Skip to main content

FDA Clears IQuum's Influenza A/B Assay

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has given 510(k) clearance to IQuum's assay for detecting and differentiating influenza A and B in about 20 minutes, the company announced today.

IQuum's Liat Influenza A/B Assay and Liat Analyzer is an automated sample-to-result multiplex real-time RT-PCR assay intended for use in CLIA-certified laboratories. According to IQuum, it is the only test that has sensitivity and specificity equivalent to or better than current lab-based nucleic acid tests, as well as time to result and ease of use comparable to immunoassays.

The assay, which is also CE marked, requires one minute of operator hands-on time and can achieve results in about 20 minutes, making it appropriate for hospital near-patient settings, the Marlborough, Mass.-based firm said.

"IQuum's goal is to provide sophisticated nucleic acid tests that can be performed in near-patient settings and deliver accurate results to physicians and patients instantly," IQuum CEO Shuqi Chen said in a statement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.